NATIONAL HARBOR, MD—The Absorb bioresorbable scaffold may not have panned out in large randomized clinical trials, but that doesn’t mean the technology is dead or that companies are necessarily put ...
MANNHEIM, Germany, and PARIS, France—Serial coronary imaging of patients implanted with a resorbable magnesium scaffold (Dreams 3G; Biotronik) for coronary artery disease suggests “favorable healing” ...
Reva Medical has secured (PDF) the CE marking of its bioresorbable scaffold. The European regulatory nod clears Reva to push a device it thinks addresses some shortcomings of other products in the ...
It was back to the drawing board for bioresorbable vascular scaffolds (BVS), to some degree, after the initially promising ABSORB series of trials dampened any enthusiasm for the coronary stent-like ...
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- The Fantom bioresorbable scaffold from REVA Medical, Inc. (ASX:RVA) shows continued positive clinical outcomes according to an interim data set from the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A ...
A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback